The Heart Loves Double Agents: Why Tirzepatide Has Overtaken Semaglutide
A dual-incretin ‘double agent’ just cut heart-failure deaths by 38% nearly twice semaglutide’s record. Here’s how it did it. As cardiologists scrolled anxiously through updates […]